News Release 

Insilico to present at the 65th IPSF World Congress

InSilico Medicine, Inc.


IMAGE: Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant at Insilico Medicine, to present at the 65th IPSF World Congress in Kigali, Rwanda. view more 

Credit: Insilico Medicine

Thursday, August 1, 2019 - Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI at the 65th IPSF World Congress on August 1, in Kigali, Rwanda.

"We are pleased to be part of the 65th IPSF World Congress which is also meant to celebrate the 70th anniversary of the IPSF, to discuss AI in healthcare: past, present and future with the professionals working to accelerate developments in pharma and healthcare, not just in Africa but in many other parts of the world. The topic of artificial intelligence in healthcare is extremely important for the countries in Africa, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant at Insilico Medicine.

The 65th IPSF World Congress is the main event of the Federation and will convene from July 30 to August 8, 2019. The 2019 Congress will mark the IPSF 70th anniversary as well as the 65th anniversary of the World Congress. The Congress is expected to bring together up to 3,000 delegates and most influential AI and emerging technology leaders to understand and experience the technology landscape trends and get the latest governmental and academic opinions on the opportunities and challenges for applications of AI and emerging technology.

The increased availability of data and recent advancements in Artificial Intelligence (AI) present the unprecedented opportunities in healthcare and major challenges for the patients, developers, providers and regulators.

The presentation will cover the latest advances in artificial intelligence and blockchain technologies that accelerate the biomedical research and enable patients to control and benefit from their medical data, that might serve as an incentive to undergo constant health monitoring in Africa.


For further information, images or interviews, please contact:

Contact: Klug Gehilfe


Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D sites and management resources in the US, Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in artificial intelligence for biomarker discovery, target identification, generation of novel chemistry and aging research.

Since 2015 Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video:


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.